CAJ | 학술논문

目的：初步探讨扩散峰度成像(DKI)在前列腺癌诊断中的作用以及在评估前列腺癌侵袭性中的价值。方法回顾性分析30例前列腺癌患者术前 MR 及多 b 值扩散加权成像(DWI)资料。分别采用 DKI 模型和单指数衰减模型计算 D 图、K 图以及表观扩散系数(ADC)图。分析比较各参数在前列腺癌与良性组织间以及不同 Gleason 评分前列腺癌间的差异。P <0.05认为差异有统计学意义。结果前列腺癌的 ADC 和 D 值均显著低于良性组织(P<0.001),而前列腺癌的 K 值显著高于良性组织(P <0.001)。ADC值、D 值和 K 值在不同 Gleason 评分(6,7及≥8)的病灶中均存在显著性差异(P <0.001、P =0.015和 P <0.001)。结论 DKI 模型可以较好地模拟前列腺癌扩散信号随 b 值的变化,有助于前列腺癌的诊断与分级。K 值有望从微观角度对前列腺癌组织微结构复杂性进行定量评估。
목적：초보탐토확산봉도성상(DKI)재전렬선암진단중적작용이급재평고전렬선암침습성중적개치。방법회고성분석30례전렬선암환자술전 MR 급다 b 치확산가권성상(DWI)자료。분별채용 DKI 모형화단지수쇠감모형계산 D 도、K 도이급표관확산계수(ADC)도。분석비교각삼수재전렬선암여량성조직간이급불동 Gleason 평분전렬선암간적차이。P <0.05인위차이유통계학의의。결과전렬선암적 ADC 화 D 치균현저저우량성조직(P<0.001),이전렬선암적 K 치현저고우량성조직(P <0.001)。ADC치、D 치화 K 치재불동 Gleason 평분(6,7급≥8)적병조중균존재현저성차이(P <0.001、P =0.015화 P <0.001)。결론 DKI 모형가이교호지모의전렬선암확산신호수 b 치적변화,유조우전렬선암적진단여분급。K 치유망종미관각도대전렬선암조직미결구복잡성진행정량평고。
Objective To evaluate the feasibility of diffusion kurtosis imaging (DKI)in the diagnosis and aggressiveness assessment of prostate cancer.Methods The MR data with multi-b-value diffusion-weighted imaging (DWI)of 30 male patients with prostate cancer were retrospectively analyzed.D maps and K maps were generated from the DKI model and ADC maps were obtained using the conventional monoexponential model.Differences in the D,K and ADC values between prostate cancer and benign peripheral zone (PZ)tissues,among tumors with different Gleason scores were analyzed.P<0.05 was considered statistical significance.Results ADC and D values were significantly lower in the prostate cancers than in the benign PZs (P <0.001).K values were significantly greater in the prostate cancers than in the benign PZs (P <0.001).ADC,D and K values were different significantly among the tumors with Glea-son scores of 6,7 and ≥8 (P <0.001,P =0.01 5 and P <0.001,respectively).Conclusion The DKI model can better describe the signal intensity attenuation with b values increasing,which is helpful for diagnosing and grading prostate cancer.K value may be used to quantitatively evaluate the complicated microstructure of prostate cancer.